Host: Jennifer Caudle, DO

Guest: Victor F. Tapson, MD

Please see the full Prescribing Information here.

This program is intended for US healthcare professionals only and is not certified for continuing medical education. Sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson, the marketer and distributor of UPTRAVI® (selexipag).

Although there is currently no cure, the treatment of pulmonary arterial hypertension (PAH) has evolved substantially and its impact on patients varies based on clinical factors, including etiology, functional class, and hemodynamic parameters.

Dr. Jennifer Caudle is joined by pulmonologist Dr. Victor Tapson, Professor of Medicine at Cedars-Sinai Medical Center, to discuss results from the Prostacyclin International Expert Panel consensus survey on common clinical scenarios in which they considered adding oral prostacyclin pathway agents in patients with PAH.

ABOUT THE PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS OPINIONS
The Prostacyclin International Expert Panel was not a consensus conference such as one held by a task force convened for the purpose of developing treatment guidelines. The Prostacyclin International Expert Panel opinion survey statements are not intended to be formal treatment guidelines or recommendations, and survey results presented here must be validated with rigorous prospective studies. The Prostacyclin International Expert Panel opinion survey statements cannot replace assessment and/or ...